Latest Stocks: Zacks: Analysts Expect American Renal Associates Holdings Inc (ARA) Will Post Earnings of $0.13 Per Share

Latest Stocks: Zacks: Analysts Expect American Renal Associates Holdings Inc (ARA) Will Post Earnings of $0.13 Per Share

Wall Street brokerages forecast that American Renal Associates Holdings Inc (NYSE:ARA) will post earnings per share (EPS) of $0.13 for the current quarter, Zacks reports. Three analysts have provided estimates for American Renal Associates Holdings’ earnings, with estimates ranging from $0.11 to $0.13. American Renal Associates Holdings reported earnings per share of $0.26 during the same quarter last year, which would indicate a negative year over year growth rate of 50%. The firm is scheduled to report its next quarterly earnings results on Tuesday, August 8th.

According to Zacks, analysts expect that American Renal Associates Holdings will report full year earnings of $0.53 per share for the current financial year, with EPS estimates ranging from $0.50 to $0.57. For the next financial year, analysts forecast that the company will report earnings of $0.69 per share, with EPS estimates ranging from $0.65 to $0.74. Zacks’ EPS averages are an average based on a survey of research analysts that cover American Renal Associates Holdings.

American Renal Associates Holdings (NYSE:ARA) last issued its quarterly earnings results on Tuesday, May 9th. The company reported $0.06 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.10 by $0.04. The firm had revenue of $177 million during the quarter, compared to analysts’ expectations of $184.67 million. American Renal Associates Holdings had a return on equity of 55.06% and a net margin of 1.92%. American Renal Associates Holdings’s revenue for the quarter was up 2.8% on a year-over-year basis. During the same period in the previous year, the company earned $0.16 earnings per share. A number of equities research analysts have recently issued reports on the stock. Zacks Investment Research upgraded shares of American Renal Associates Holdings from a “sell” rating to a “hold” rating in a research report on Tuesday. Wells Fargo & Co upgraded shares of American Renal Associates Holdings from a “market perform” rating to an “outperform” rating in a research report on Thursday, May 11th. Finally, Barclays PLC reduced their price target on shares of American Renal Associates Holdings from $25.00 to $23.00 and set an “overweight” rating for the company in a research report on Thursday, March 9th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $27.00.

Large investors have recently bought and sold shares of the stock. Endurant Capital Management LP bought a new stake in American Renal Associates Holdings during the first quarter worth about $776,000. Bank of America Corp DE boosted its position in shares of American Renal Associates Holdings by 21.6% in the first quarter. Bank of America Corp DE now owns 29,837 shares of the company’s stock worth $504,000 after buying an additional 5,296 shares during the period. Schwab Charles Investment Management Inc. boosted its position in shares of American Renal Associates Holdings by 7.1% in the first quarter. Schwab Charles Investment Management Inc. now owns 38,847 shares of the company’s stock worth $656,000 after buying an additional 2,565 shares during the period. Lucus Advisors LLC acquired a new position in shares of American Renal Associates Holdings during the first quarter worth $295,000. Finally, Morgan Stanley boosted its position in shares of American Renal Associates Holdings by 17.4% in the first quarter. Morgan Stanley now owns 40,305 shares of the company’s stock worth $681,000 after buying an additional 5,968 shares during the period. Institutional investors own 87.52% of the company’s stock. Shares of American Renal Associates Holdings (NYSE:ARA) traded up 2.20% during midday trading on Friday, reaching $17.21. The company had a trading volume of 24,850 shares. The firm’s 50 day moving average price is $17.20 and its 200-day moving average price is $19.89. The stock’s market capitalization is $535.97 million. American Renal Associates Holdings has a 1-year low of $15.47 and a 1-year high of $29.65.

Large investors have recently bought and sold shares of the stock. Endurant Capital Management LP bought a new stake in American Renal Associates Holdings during the first quarter worth about $776,000. Bank of America Corp DE boosted its position in shares of American Renal Associates Holdings by 21.6% in the first quarter. Bank of America Corp DE now owns 29,837 shares of the company’s stock worth $504,000 after buying an additional 5,296 shares during the period. Schwab Charles Investment Management Inc. boosted its position in shares of American Renal Associates Holdings by 7.1% in the first quarter. Schwab Charles Investment Management Inc. now owns 38,847 shares of the company’s stock worth $656,000 after buying an additional 2,565 shares during the period. Lucus Advisors LLC acquired a new position in shares of American Renal Associates Holdings during the first quarter worth $295,000. Finally, Morgan Stanley boosted its position in shares of American Renal Associates Holdings by 17.4% in the first quarter. Morgan Stanley now owns 40,305 shares of the company’s stock worth $681,000 after buying an additional 5,968 shares during the period. Institutional investors own 87.52% of the company’s stock. American Renal Associates Holdings Company Profile

American Renal Associates Holdings, Inc is a dialysis service provider in the United States focused on joint venture (JV) partnerships with physicians. As of December 31, 2016, the Company owned and operated 214 dialysis clinics in partnership with 379 nephrologist partners treating over 14,000 patients in 25 states and the District of Columbia.

Get a free copy of the Zacks research report on American Renal Associates Holdings (ARA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com Receive News & Ratings for American Renal Associates Holdings Inc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for American Renal Associates Holdings Inc and related companies with MarketBeat.com’s FREE daily email newsletter.

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Related posts

Leave a Comment